Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | The safety and efficacy of parsaclisib in autoimmune hemolytic anemia

Ulrich Jäger • 10 Jun 2022
EHA 2022
Anemias Autoimmune Hemolytic Anemia Cold Agglutinin Disease Non-Malignant Parsaclisib

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the results of a study evaluating the safety and efficacy of parsaclisib for the treatment of warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies 1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia 1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries 1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy 0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention 4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025
The role of inflammation in SCD pathophysiology and potential avenues for targeting it 6:48
The role of inflammation in SCD pathophysiology and potential avenues for targeting it
Subarna Chakravorty • 3 Nov 2025
The management of thalassemia in India 2:16
The management of thalassemia in India
Shruti Kakkar • 15 Oct 2025
The potential role of thalidomide in the treatment of thalassemia 2:33
The potential role of thalidomide in the treatment of thalassemia
Shruti Kakkar • 15 Oct 2025
The content of VJHemOnc is intended for healthcare professionals